Animal models for drug discovery in dystonia

Expert Opinion on Drug Discovery

Volumn 3, Issue 1, 2008, Pages 83-97

  Jinnah, H A ^a   Richter, Angelika ^b   Mink, Jonathon W ^c   Caldwell, Guy A ^d   Caldwell, Kim A ^d   Gonzalez Alegre, Pedro ^e   Cookson, Mark R ^f   Breakefield, Xandra O ^g   Delong, Mahlon R ^h   Hess, Ellen J ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

^c UNIVERSITY OF ROCHESTER   (United States)

^d UNIVERSITY OF ALABAMA   (United States)

^e UNIVERSITY OF IOWA   (United States)

^f NATIONAL INSTITUTE ON AGING   (United States)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

^h EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Animal model; Caenorhabditis elegans; Dystonia; Experimental therapeutics; Hamster; Mouse; Primate; Rat

Indexed keywords

ACETAZOLAMIDE; AMINOOXYACETIC ACID; ANTIPARKINSON AGENT; BACLOFEN; BENZODIAZEPINE; BENZODIAZEPINE DERIVATIVE; BOTULINUM TOXIN; CHAPERONE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; DIAZEPAM; DILTIAZEM; DIZOCILPINE; ETIRACETAM; FLUPIRTINE; GABAPENTIN; HALOPERIDOL; LEVODOPA; MEMANTINE; MUSCIMOL; MUSCLE RELAXANT AGENT; NIMODIPINE; PHENOBARBITAL; PINDOLOL; RETIGABINE; TIAGABINE; TORSIN 1A; TRIHEXYPHENIDYL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VOLTAGE GATED CALCIUM CHANNEL;

AMYOTROPHIC LATERAL SCLEROSIS; DISEASE CLASSIFICATION; DRUG DESIGN; DRUG EFFICACY; DRUG RESEARCH; DRUG TARGETING; DYSTONIA; EMPIRICAL RESEARCH; EPILEPSY; HUMAN; INVOLUNTARY MOVEMENT; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PHENOTYPIC VARIATION; PRIMATE; PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE; RODENT; UNSPECIFIED SIDE EFFECT;

EID: 38849110026     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460441.3.1.83     Document Type: Review

References (79)

1. Fahn S. The varied clinical expressions of dystonia. Neurol Clin 1984;2:541-54
2. Fahn S. Concept and classification of dystonia. Adv Neurol 1988;50:1-8
3. Bressman SB. Dystonia: phenotypes and genotypes. Rev Neurol 2003;159:849-56
4. Nemeth AH. The genetics of primary dystonias and related disorders. Brain 2002;125:695-721
5. Decarvalho Aguiar PM, Ozelius LJ. Classification and genetics of dystonia. Lancet Neurol 2002;1:316-25
6. Defazio G. Epidemiology of primary and secondary dystonia. In: Handbook of Dystonia. Stacey ME (Ed.), New York, USA: Informa Healthcare; 2007. p. 11-20
7. Tolosa E, Compta Y. Dystonia in Parkinson's disease. J Neurol 2006;253(Suppl 7):7-13
8. Jankovic J, Tintner R. Dystonia and parkinsonism. Parkinsonism Rel Disord 2001;8:109-21
9. Sanger TD, Delgado MR, Gaebler-Spira D, et al. Classification and definition of disorders causing hypertonia in childhood. Pediatrics 2003;111:89-97
10. Kyllerman M, Bager B, Bensch J, et al. Dyskinetic cerebral palsy. I. Clinical categories, associated neurological abnormalities and incidences. Acta Pediatr Scand 1982;71:543-50
11. Albright AL, Barry MJ, Shafron DH, Ferson SS. Intrathecal baclofen for generalized dystonia. Dev Med Child Neurol 2001;43:652-7
12. Jankovic J. Treatment of dystonia. Lancet Neurol 2006;5:864-72
13. Albanese A, Barnes MP, Bhatia KP, et al. A systematic review on the diagnosis and treatment of primary (idiopathic) dystonia and dystonia plus syndromes: repor of an EFNS/MDS-ES task force. Eur J Neurol 2006; 13:433-44
14. Greene P. Baclofen in the treatment of dystonia. Clin Neuropharmacol 1992;15:276-88
15. Walker RH, Danisi FO, Swope DM, et al. Intrathecal baclofen for dystonia: benefits and complications during six years of experience. Mov Disord 2000; 15:1242-7
16. Arce CA. Selective denervation in cervical dystonia. In: Handbook of dystonia. Stacey MA (Ed.), New York, USA: Informa Healthcare; 2007. p. 381-92
17. Marks WJJ. Brain surgery for dystonia. In: Handbook of Dystonia. Stacey MA (Ed.), New York, USA: Informa Healthcare; 2007. p. 393-406
18. Jinnah HA, Hess EJ, Ledoux MS, et al. Rodent models for dystonia research: characteristics, evaluation, and utility. Mov Disord 2005;20:283-92
19. Ozelius LJ, Hewett JW, Page CE, et al. The early-onset torsion dystonia gene (DYT1) encodes an ATP-binding protein. Nat Genet 1997;17:408
20. Hewett JW, Gonzalez-Agosti C, Slater D, et al. Mutant torsinA, responsible for early-onset torsion dystonia, forms membrane inclusions in cultured neural cells. Hum Mol Genet 2000;9:1403-13
21. Goodchild RE, Kim CE, Dauer WT. Loss of the dystonia-associated protein torsinA selectively disrupts the neuronal nuclear envelope. Neuron 2005;48:923-32
22. Shashidharan P, Sandu D, Potla U, et al. Transgenic mouse model of early-onset dyt1 dystonia. Hum Mol Genet 2005;14(1):125-33
23. Sharma N, Baxter MG, Petravicz J, et al. Impaired motor learning in mice expressing torsinA with the dyt1 dystonia mutation. J Neurosci 2005;25(22):5351-5
24. Grundmann M, Reischmann B, Vanhoutte G, et al. Overexpression of human wildtype torsinA and human deltaGAG torsinA in a transgenic mousemodel causes phenotypic abnormalities. Neurobiol Dis 2007;27:19-206
25. Dang MT, Yokoi F, McNaught KS, et al. Generation and characterization of Dyt1 deltaGAG knock-in mouse as a model for early-onset dystonia. Exp Neurol 2005;196:452-63
26. Duchen LW. Dystonia musculorum - an inherited disease of the nervous system in the mouse. Adv Neurol 1976;14:353-65
27. Lorden JF, McKeon TW, Baker HJ, et al. Characterization of the rat mutant dystonic (dt): a new animal model of dystonia musculorum deformans. J Neurosci 1984;4:1925-32
28. Loscher W, Fisher JE, Schmidt D, et al. The sz mutant hamster: a genetic model of epilepsy or of paroxysmal dystonia? Mov Disord 1989;4:219-32
29. Richter A, Loscher W. Pathology of idiopathic dystonia: findings from genetic animal models. Prog Neurobiol 1998;54:633-77
30. Gernert M, Bennay M, Fedrowitz M, et al. Altered discharge pattern of basal ganglia output neurons in an animal model of idiopathic dystonia. J Neurosci 2002;22:7244-53
31. Fletcher CF, Lutz CM, O'Sullivan TN, et al. Absence epilepsy in tottering mutant mice is associated with calcium channel defects. Cell 1996;87:607-17
32. Wakamori M, Yamazaki K, Matsunodaira H. Single tottering mutations responsible for the neuropathic phenotype of the P-type calcium channel. J Biol Chem 1998;52:34857-67
33. Campbell DB, Hess EJ. Cerebellar circuitry is activated during convulsive episodes in the tottering (tg/tg) mutant mouse. Neuroscience 1998;85:773-83
34. Campbell DB, North JB, Hess EJ. Tottering mouse motor dysfunction is abolished on the Purkinje cell degeneration (pcd) mutant background. Exp Neurol 1999; 160:268-78
35. Byl NN. Focal hand dystonia may result from aberrant neuroplasticity. Adv Neurol 1994;94:19-28
36. Mink JW, Thach WT. Basal ganglia motor control. III. Pallidal ablation: normal reaction time, muscle cocontraction, and slow movement. J Neurophysiol 1991;65:330-51
37. Burns LH, Pakzaban P, Deacon TW, et al. Selective putaminal excitotoxic lesions in non-human primates model the movement disorder of Huntington disease. Neuroscience 1995;64:1007-17
38. Foltz EL, Knopp LM, Ward AA. Experimental spasmodic torticollis. J Neurosurg 1959;16:55-67
39. Malouin F, Bedard PJ. Frontal torticollis (head tilt) induced by electrolytic lesion and kainic acid injection in monkeys and cats. Exp Neurol 1982;78:551-60
40. Klier EM, Wang H, Constantin AG, Crawford JD. Midbrain control of three-dimensional head orientation. Science 2002;295:1314-16
41. Marsden CD, Obeso JA, Zarranz JJ. The anatomical basis of symptomatic dystonia. Brain 1985;108:463-83
42. Perlmutter JS, Tempel LW, Black KJ, et al. MPTP induces dystonia and parkinsonism. Clues to the pathophysiology of dystonia. Neurology 1997;49:1432-8
43. Tabbal SD, Mink JW, Antenor JAV, et al. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced acute transient dystonia in monkeys with low striatal dopamine. Neuroscience 2006; 141:1281-7
44. Boyce S, Clarke CE, Luguin R, et al. Induction of chorea and dystonia in Parkinsonian primates. Mov Disord 1990;5:3-7
45. Olanow CW, Good PF, Shinotoh H, et al. Manganese intoxication in the rhesus monkey: a clinical, imaging, pathologic, and biochemical study. Neurology 1996;46:492-8
46. Ghorayeb I, Fernagut PO, Stefanova N, et al. Dystonia is predictive of subsequent altered dopaminergic responsiveness in a chronic 1-methyl4-phenyl-1,2,3,6-tetrahydropyridine + 3-nitropropionic acid model of striatonigral degeneration in monkeys. Neurosci Lett 2002;335:34-8
47. Brouillet E, Hantraye P, Ferrante RJ, et al. Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. Proc Natl Acad Sci USA 1995;92:7105-9
48. Segalat L. Invertebrate animal models of diseases as screening tools in drug discovery. ACS Chem Biol 2007;2:231-6
49. Caldwell GA, Cao S, Izevbaye I, Caldwell KA. Use of C. elegans to model human movement disorders. In: Animal Models of Movement Disorders. LeDoux MS (Ed.), Burlington, USA: Elsevier; 2005. p. 111-26
50. Betarbet R, Sherer TB, Greenamyre JT. Animal models of Parkinson's disease. Bioessays 2002;24:308-18
51. Hirsch EC, Hoglinger G, Rousselet E, et al. Animal models of Parkinson's disease in rodents induced by toxins: an update. Neural Transm Suppl 2003;65:89-100
52. Moore DJ, West AB, Dawson VL, Dawson TM. Molecular pathophysiology of Parkinson's disease. Ann Rev Neurosci 2005;28:57-87
53. Cookson MR. The biochemistry of Parkinson's disease. Annu Rev Biochem 2005;74:29-52
54. Benatar M. Lost in translation: treatment trials in the SOD1 mouse and in human ALS. Neurobiol Dis 2007;26:1-13
55. Friese MA, Montalban X, Willcox N, et al. The value of animal models for drug development in multiple sclerosis. Brain 2006; 129:1940-52
56. Cheng YD, Al-Khoury L, Zivin JA. Neuroprotection for ischemic stroke: two decades of success and failure. NeuroRx 2004; 1:36-45
57. Gladstone DJ, Black SE, Hakim AM. Toward wisdom from failure: lessons from neuroprotective stroke trials and new therapeutic directions. Stroke 2002;33:2123-36
58. Green AR, Odergren T, Ashwood T. Animal models of stroke: do they have value for discovering neuroprotective agents? Trends Pharmacol Sci 2003;24:402-8
59. O'Collins VE, MacLeod MR, Donnan GA, et al. 1,026 experimental treatments in acute stroke. Ann Neurol 2006;59:467-77
60. Rogawski MA. Molecular targest versus modesl for new antiepileptic drug discovery. Epilepsy Res 2006;68:22-8
61. Gonzalez-Alegre P, Bode N, Davidson BL, Paulson HL. Silencing primary dystonia: lentiviral-mediated RNA interference therapy for DYT1 dystonia. J Neurosci 2005;25:10502-9
62. Caldwell GA, Cao S, Sexton EG, et al. Suppression of polyglutamine-induced protein aggregation in Caenorhabditis elegans by torsin proteins. Hum Mol Genet 2003;12:307-19
63. Richter A, Sander SE, Rundfeldt C. Antidystonic effects of Kv7 (KCNA) channel openers in the dt sz mutant, an animal model of primary paroxsymal dystonia. Br J Pharmacol 2006; 149:747-53
64. Hess EJ, Jinnah HA. Mouse models of dystonia. In: Animal Models of Movement Disorders. Le Doux MS (Ed.), San Diego, USA: Elsevier; 2005. p. 265-77
65. Giffin NJ, Benton S, Goadsby PJ. Benign paroxysmal torticollis of infancy: four new cases and linkage m CACNA1A mutation. Dev Med Child Neurol 2002;44:490-3
66. Spacey SD, Materek LA, Szczygielski BI, Bird TD. Two novel CACNA1A gene mutations associated with episodic ataxia type 2 and interictal dystonia. Arch Neurol 2005;62:314-16
67. Jinnah HA, Sepkuty JP, Ho T, et al. Calcium channel agonists and dystonia in the mouse. Mov Disord 2000;15:542-51
68. Street VA, Bosma MM, Demas VP, et al. The type 1 inositol triphosphate receptor gene is altered in the opisthotonus mouse. J Neurosci 1997;17:635-47
69. Matsumoto M, Nakagawa T, Inoue T, et al. Ataxia and epileptic seizures in mice lacking type 1 inositol 1,4,5-triphosphate receptor. Nature 1996;379:168-71
70. Campbell DB, Hess EJ. L-type calcium channels contribute to the tottering mouse dystonic episodes. Mol Pharmacol 1999;55:23-31
71. Khan Z, Carey J, Park HJ, et al. Abnormal motor behavior and vestibular dysfunction in the stargazer mouse mutant. Neuroscience 2004;127:785-96
72. Khan Z, Jinnah HA. Paroxysmal dyskinesias in the lethargic mouse mutant. J Neurosci 2002;22:8193-200
73. Richter A, Loscher W. Antidystonic effects of L-type Ca2+ channel antagonists in a hamster model of idiopathic dystonia. Eur J Pharmacol 1996;300:197-202
74. Cates M, Lusk K, Wells BG. Are calcium-channel blockers effective in the treatment of tardive dyskinesia? Ann Pharmacother 1993;27:191-6
75. Perlmutter JS, Mink JW. Dysfunction of dopaminergic pathways in dystonia. Adv Neurol 2004;94:163-70
76. Hallett M. Pathophysiology of dystonia. J Neural Transm Suppl 2006;70:485-8
77. Quartarone A, Siebner HR, Rothwell JC. Task-specific hand dystonia: can too much plasticity be bad for you? Trends Neurosci 2006;29:192-9
78. Eriksen JL, Wszolek Z, Petrucelli L. Molecular pathogenesis of Parkinson disease. Arch Neurol 2005;62:353-7
79. Balcioglu A, Kim MO, Sharma N, et al. Dopamine release is impaired in a mouse model of DYT1 dystonia. J Neurochem 2007;102:783-8